Doramapimod (BIRB 796)
中文名称:达马莫德
目录号:S1574 Purity: 99.99%
Doramapimod (BIRB 796)是一种泛p38 MAPK抑制剂,在无细胞试验中作用于p38α/β/γ/δ的IC50分别为38 nM,65 nM,200 nM 和520 nM,并且能够与p38α结合,在THP-1细胞中Kd为0.1 nM,比作用于JNK2选择性高330倍,对c-RAF,Fyn 和Lck具有较弱的抑制作用,对ERK-1,SYK,IKK2也有微弱抑制作用。
CAS: 285983-48-4
客户使用Selleck的Doramapimod (BIRB 796)发表文献123篇
- Cancer Discov, 2022 12(6):1542-1559
- Immunity, 2021 S1074-7613(21)00403-9
- Nature, 2020 3
- Cell, 2020 182(3):685-712.e19
- J Hepatol, 2019 71(1):163-174
- Blood, 2018 131(11):1219-1233
- Blood, 2016 128(25):2988-2999
- Mol Cancer, 2014 13:40
- Cell Host Microbe, 2013 13(1):67-76
- Blood, 2012 119(26):6255-8
- J Immunother Cancer, 2024 12(6)e009082
- Aging Cell, 2024 e14093.
- EMBO Rep, 2024 10.1038/s44319-024-00149-y
- iScience, 2024 27(8):110598
- Biochem J, 2024 481(6):405-422
- Nat Commun, 2023 14(1):7916
- Cell Rep, 2023 42(6):112547
- Int J Mol Sci, 2023 10.3390/ijms242216538
- Biol Direct, 2023 18(1):37
- J Biol Chem, 2023 S0021-9258(23)00341-1
- J Gen Virol, 2023 104(11)001923
- J Cosmet Dermatol, 2023 10.1111/jocd.15810
- bioRxiv, 2023 10.1101/2023.04.13.536820
- Nat Commun, 2022 13(1):6672
- Cell Syst, 2022 13(11):885-894.e4
- Cell Rep, 2022 39(4):110721
- JCI Insight, 2022 7(9)e151847
- J Cell Biol, 2022 221-11e202202100
- Sci Signal, 2022 15(728):eabj6915
- Am J Cancer Res, 2022 12(10:4666-4679)
- Mol Neurobiol, 2022 59(9):5284-5298
- J Biol Chem, 2022 S0021-9258(22)00469-0
- Biology (Basel), 2022 11(1)121
- J Biochem Mol Toxicol, 2022 e23267.
- Front Neurol, 2022 13:946324
- Proc Natl Acad Sci U S A, 2021 118(38)e2102423118
- J Immunother Cancer, 2021 9(7)e002319
- Blood Adv, 2021 5(17):3497-3510
- Front Immunol, 2021 12:781352
- Int Immunopharmacol, 2021 98:107848
- Pharmaceutics, 2021 13(11)1841
- Cancers (Basel), 2021 13(18)4612
- J Mol Med (Berl), 2021 10.1007/s00109-021-02046-6
- Mol Immunol, 2021 133:135-145
- J Orthop Res, 2021 10.1002/jor.25190
- Exp Ther Med, 2021 21(5):440
- HAL open science, 2021 10.1101/2020.09.23.310235
- J Clin Invest, 2020 130(3):1377-1391
- Genome Biol, 2020 21(1):33
- Redox Biol, 2020 28:101445
- Elife, 2020 9e60541
- Mol Oncol, 2020 10.1002/1878-0261.12882
- Cells, 2020 17;9(4) pii: E1003
- J Cell Mol Med, 2020 10.1111/jcmm.16223
- Cancers (Basel), 2020 10;12(6):E1516
- Sci Rep, 2020 10(1):21364
- Cell Immunol, 2020 347:104027
- J Vet Intern Med, 2020 10.1111/jvim.15847
- Mol Biomed, 2020 1(1):12
- Nat Commun, 2019 10(1):2387
- J Allergy Clin Immunol, 2019 144(4):1036-1049
- Redox Biol, 2019 21:101061
- Pharmacol Res, 2019 143:73-85
- Arterioscler Thromb Vasc Biol, 2019 39(12):e253-e272
- Antiviral Res, 2019 170:104572
- Oncoimmunology, 2019
- Cell Death Discov, 2019 5:104
- Mol Oncol, 2019 13(2):264-289
- Life Sci, 2019 10.1016/j.lfs.2019.116583
- Eur J Pharmacol, 2019 865:172760
- J Cancer Res Clin Oncol, 2019 145(2):411-427
- Neurogastroenterol Motil, 2019 31(6):e13555
- Biochemistry, 2019 58(51):5160-5172
- J Clin Invest, 2018 128(10):4485-4500
- Cell Death Dis, 2018 9(6):703
- Aging Cell, 2018 17(1)
- Elife, 2018 7
- Sci Signal, 2018
- Oncotarget, 2018 9(51):29680-29697
- Mol Cell Biol, 2018 38(11)e00647-17
- Sci Rep, 2018 8(1):5007
- PLoS Genet, 2018 14(9):e1007621
- Invest Ophthalmol Vis Sci, 2018 59(10):4218-4227
- Biochemistry, 2018 57(48):6715-6725
- J Clin Invest, 2017 127(9):3339-3352
- Cell Death Dis, 2017 8(8):e2967
- Front Immunol, 2017 8:818
- J Mol Cell Biol, 2017 1;9(2):154-165
- Stem Cells, 2017 35(4):909-919
- Mol Neurobiol, 2017 54(10):7597-7609
- Development, 2017 144(12):2270-2281
- J Cell Commun Signal, 2017
- Oncol Lett, 2017 14(3):3463-3472
- Int Immunopharmacol, 2016 35:155-162
- J Am Heart Assoc, 2016 5(8)
- Sci Rep, 2016 6:28655
- Am J Physiol Gastrointest Liver Physiol, 2016 310(8):G539-49
- Invest Ophthalmol Vis Sci, 2016 57(14):6461-6473
- Cancer Biol Ther, 2016 17(5):566-76
- J Exp Med, 2015 212(4):525-38
- EBioMedicine, 2015 2(12):1944-56
- Mol Syst Biol, 2015 11(3):797
- Cell Death Dis, 2015 6:e1781
- J Med Chem, 2015 58(1):466-79
- Matrix Biol, 2015 48:66-77
- Stem Cell Reports, 2015 4(3):489-502
- Eur J Immunol, 2015
- Sci Rep, 2015 5:15911
- Stem Cell Reports, 2014 3(1):34-43
- Exp Gerontol, 2014 52:55-69
- PLoS One, 2014 9(7):e103578
- Genes Cancer, 2014 5(9-10):353-64
- Nat Chem Biol, 2013 9(7):428-36
- Int J Cancer, 2013 134(3):575-86
- Eur J Pharmacol, 2013 701(1-3):96-105
- Am J Physiol Lung Cell Mol Physiol, 2013 305(10):L747-55
- J Biol Chem, 2013 288(23):16882-94
- Cell Cycle, 2013 12(13):2051-60
- Biochem J, 2013 449(2):497-506
- PLoS One, 2013 8(1):e54181
- Physiol Rep, 2013 1(5):e00078
- University of Toronto, 2013 Department of Immunology
- Cancer Lett, 2012 324(1):98-108
化学信息&溶解度
分子量 | 527.66 |
分子式 | C31H37N5O3 |
CAS号 | 285983-48-4 |
Smiles | CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCCN5CCOCC5 |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 189.51 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 189.51 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 189.51 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 189.51 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:5mg/ml
(9.48mM)
操作示例:以 1 mL 工作液为例,取50μL100mg/ml的澄清DMSO储备液加到 400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。